|
|
||||||||
J Thorac Cardiovasc Surg 2000;119:1147-1153
© 2000 The American Association for Thoracic Surgery
GENERAL THORACIC SURGERY |
From the Thoracic Surgery,a Orthopedic Surgery,b and Neurosurgery Services,c Department of Surgery, and the Biostatistics Service,d Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY.
Address for reprints: Valerie W. Rusch, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Rm C-867, New York, NY 10021 (E-mail: ruschv{at}mskcc.org ).
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Although many small surgical series attest to the feasibility of this treatment regimen (Table I), survival at 5 years remains approximately 25% to 30%. The recent success of combined modality therapy, especially induction chemotherapy, in the management of stage IIIA (N2) NSCLC has stimulated interest in applying this approach to lung cancers of the superior sulcus. As a result, the treatment of lung cancers of the superior sulcus is now in flux, with various combinations of chemotherapy and radiation often being given in the preoperative period in a highly individualized manner. A prospective multi-institutional phase II trial (Intergroup trial 0160, SWOG trial 9416) is currently underway to test the use of concurrent induction chemotherapy and radiation followed by surgical resection in both T3 and T4 N0-1 lung cancers of the superior sulcus. It is important to have a large and reliable historical experience against which to assess the validity of this new regimen.
|
| Patients and methods |
|---|
|
|
|---|
A detailed retrospective chart review was performed and the following items were recorded: patient age and sex; histologic tumor type and TNM status; type of preoperative and postoperative treatment; type of operation; whether resection was complete; disease status at last follow-up contact; and, when appropriate, date and sites of relapse. A resection was considered complete if the surgeon recorded that all gross tumor was removed and the surgical margins were histologically free of disease (negative). When not available by chart review, follow-up information was obtained by direct communication with the patient, family, or referring physician.
Statistical analyses were performed with SAS and S Plus software (SAS Institute, Inc, Cary, NC). Survival probabilities were calculated by the product limit method of Kaplan and Meier.
6 The prognostic significance of factors was tested in a univariate model by log rank statistic for categorical covariates and by proportional hazards regression for continuous covariates. Proportional hazards regression was used to test the prognostic significance of factors in a multivariable model.
6-8
| Results |
|---|
|
|
|---|
|
|
|
|
|
|
Potential prognostic factors were then also examined in a multivariable analysis (Table V). These included patient age and sex, T and N status, the type of resection performed, the type of preoperative therapy, the histologic tumor type, and the completeness of resection. Only the completeness of resection and the T and N status still had a significant impact on overall survival.
|
|
| Discussion |
|---|
|
|
|---|
During the 1980s, several reports
12-19 established the "Paulson regimen" of preoperative radiation followed by surgical resection as a standard of care that led to an approximate 30% survival at 5 years (Table I
). From this experience it appeared that N2 disease, diseased (positive) margins, and vertebral body involvement might have an adverse impact on overall survival.
4,14,20,21 However, the significance of these prognostic factors was not firmly established because published reports usually described small numbers of patients treated in variable ways over many years. Not all authors agreed on the poor prognostic impact of T4 disease so long as complete resection was achieved.
15 On the other hand, there has been a growing recognition of the importance of mediastinoscopy and the fact that N2 disease, as for all other subsets of stage III NSCLC, was associated with the early development of distant metastases and an extremely poor survival.
4,14,15
During the 1990s, reports have focused on defining prognostic factors,
5,20-22 on determining the role of brachytherapy,
5 and on exploring new techniques that facilitate complete resection of T4 tumors.
18,23 Our previous analysis, based on 124 patients operated on from 1974 to 1991, showed that brachytherapy did not contribute significantly to local control and suggested that N2 disease, completeness of resection, T4 tumors, and, to a lesser degree, limited pulmonary resection had an adverse impact on survival. Since then, mediastinoscopy, with or without scalene node biopsy, has been a routine part of our preresection evaluation of superior sulcus tumors. The neurosurgeons and orthopedic surgeons frequently participate in preoperative evaluation and surgical resection. Formal vertebral resection is performed whenever indicated to try to ensure complete resection of tumor abutting or involving the spine. Although common patterns of tumor invasion of the spine sometimes preclude en bloc resection, negative surgical margins can usually be obtained, at least for T3 tumors. However, our recent experience indicates that a complete resection is still not achieved for many T4 tumors.
Most recently, interest in exploring the potential benefit of preoperative chemotherapy has been increasing. The small series of 18 cases reported by Martínez-Monge and associates
24 suggests that induction chemoradiotherapy may improve the likelihood of pathologic complete response, local control, and overall survival. This approach to treatment is now being formally tested in a prospective multi-institutional clinical trial. Our current series, which includes almost twice the number of cases we reported previously, provides an important benchmark against which to assess the value of a new approach to treatment, because most of our patients had a surgical resection with preoperative and/or postoperative radiation with no consistent use of chemotherapy. Our current experience highlights several important aspects of the management of superior sulcus tumors. In addition to emphasizing the impact of T and N status on overall survival, it clearly demonstrates the importance of complete resection and the fact that only approximately half of all tumors are amenable to complete resection when managed in the traditional manner. Although the rates of complete resectability and 5-year survival are better for T3 N0 tumors (64% and 46%, respectively) than for the other TN subsets, they are still unacceptably low. This problem is not usually emphasized, but a review of published series (Table I
) indicates that our rate of incomplete resection is similar to that reported by other authors. Locoregional recurrence remains the predominant form of relapse for both T3 and T4 tumors, although this is obviously a greater problem for T4 tumors involving the spine. Future efforts to improve the results will entail not only a multidisciplinary approach to en bloc extended resection of adjacent structures, most frequently the spine, but also preoperative therapy that yields greater tumor regression, thereby improving the rates of complete resection that are so critical to long-term survival in this form of NSCLC.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
B. D. T. Daly, M. I. Ebright, A. J. Walkey, H. C. Fernando, K. S. Zaner, D. M. Morelli, and L. A. Kachnic Impact of neoadjuvant chemoradiotherapy followed by surgical resection on node-negative T3 and T4 non-small cell lung cancer J. Thorac. Cardiovasc. Surg., June 1, 2011; 141(6): 1392 - 1397. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tamura, M. A. Hoda, and W. Klepetko Current treatment paradigms of superior sulcus tumours Eur J Cardiothorac Surg, October 1, 2009; 36(4): 747 - 753. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. D. Bolton, D. C. Rice, A. Goodyear, A. M. Correa, J. Erasmus, W. Hofstetter, R. Komaki, R. Mehran, K. Pisters, J. A. Roth, et al. Superior sulcus tumors with vertebral body involvement: A multimodality approach. J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1379 - 1387. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Bruzzi, R. Komaki, G. L. Walsh, M. T. Truong, G. W. Gladish, R. F. Munden, and J. J. Erasmus Imaging of Non-Small Cell Lung Cancer of the Superior Sulcus: Part 1: Anatomy, Clinical Manifestations, and Management RadioGraphics, March 1, 2008; 28(2): 551 - 560. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Bruzzi, R. Komaki, G. L. Walsh, M. T. Truong, G. W. Gladish, R. F. Munden, and J. J. Erasmus Imaging of Non-Small Cell Lung Cancer of the Superior Sulcus: Part 2: Initial Staging and Assessment of Resectability and Therapeutic Response RadioGraphics, March 1, 2008; 28(2): 561 - 572. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kunitoh, H. Kato, M. Tsuboi, T. Shibata, H. Asamura, Y. Ichonose, N. Katakami, K. Nagai, T. Mitsudomi, A. Matsumura, et al. Phase II Trial of Preoperative Chemoradiotherapy Followed by Surgical Resection in Patients With Superior Sulcus Non-Small-Cell Lung Cancers: Report of Japan Clinical Oncology Group Trial 9806 J. Clin. Oncol., February 1, 2008; 26(4): 644 - 649. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Leo, P. Solli, G. Veronesi, G. Catalano, T. De Pas, F. Petrella, and L. Spaggiari Induction Chemoradiotherapy for Superior Sulcus Non-Small-Cell Lung Cancer: An Answer for Few J. Clin. Oncol., May 20, 2007; 25(15): 2146 - 2146. [Full Text] [PDF] |
||||
![]() |
V. W. Rusch In Reply J. Clin. Oncol., May 20, 2007; 25(15): 2147 - 2147. [Full Text] [PDF] |
||||
![]() |
V. W. Rusch, D. J. Giroux, M. J. Kraut, J. Crowley, M. Hazuka, T. Winton, D. H. Johnson, L. Shulman, F. Shepherd, C. Deschamps, et al. Induction Chemoradiation and Surgical Resection for Superior Sulcus Non-Small-Cell Lung Carcinomas: Long-Term Results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160) J. Clin. Oncol., January 20, 2007; 25(3): 313 - 318. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Marra, W. Eberhardt, C. Pottgen, D. Theegarten, S. Korfee, T. Gauler, M. Stuschke, and G. Stamatis Induction chemotherapy, concurrent chemoradiation and surgery for Pancoast tumour Eur. Respir. J., January 1, 2007; 29(1): 117 - 126. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Spaggiari, M. D'Aiuto, G. Veronesi, F. Leo, P. Solli, M. Elena Leon, R. Gasparri, D. Galetta, F. Petrella, A. Borri, et al. Anterior approach for Pancoast tumor resection MMCTS, January 1, 2007; 2007(1018): mmcts.2005.001776 - mmcts.2005.001776. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Farray, N. Mirkovic, and K. S. Albain Multimodality Therapy for Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., May 10, 2005; 23(14): 3257 - 3269. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Goldberg, D. Gupta, A. R. Sasson, B. Movsas, C. J. Langer, A. L. Hanlon, H. Wang, and W. J. Scott The Surgical Management of Superior Sulcus Tumors: A Retrospective Review With Long-Term Follow-Up Ann. Thorac. Surg., April 1, 2005; 79(4): 1174 - 1179. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. C. Archie and C. R. Thomas Jr. Superior Sulcus Tumors: A Mini-Review Oncologist, September 1, 2004; 9(5): 550 - 555. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. M. Pitz, A. B. de la Riviere, H. A. van Swieten, V. A. M. Duurkens, J.-W. J. Lammers, and J. M. M. van den Bosch Surgical treatment of Pancoast tumours Eur J Cardiothorac Surg, July 1, 2004; 26(1): 202 - 208. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF] |
||||
![]() |
A. N. van Geel, P. P. Jansen, R. J. van Klaveren, and J. R. M. van der Sijp High Relapse-Free Survival After Preoperative and Intraoperative Radiotherapy and Resection for Sulcus Superior Tumors Chest, November 1, 2003; 124(5): 1841 - 1846. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Alifano, M. D'Aiuto, P. Magdeleinat, E. Poupardin, A. Chafik, S. Strano, and J. F. Regnard Surgical Treatment of Superior Sulcus Tumors: Results and Prognostic Factors Chest, September 1, 2003; 124(3): 996 - 1003. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Spaggiari Anterior approach versus posterior approach in apical chest tumor: surgeon's choice or oncological need? Ann. Thorac. Surg., February 1, 2003; 75(2): 633 - 634. [Full Text] [PDF] |
||||
![]() |
E. Martinod, A. D'Audiffret, P. Thomas, A. J. Wurtz, M. Dahan, M. Riquet, A. Dujon, R. Jancovici, R. Giudicelli, P. Fuentes, et al. Management of superior sulcus tumors: experience with 139 cases treated by surgical resection Ann. Thorac. Surg., May 1, 2002; 73(5): 1534 - 1539. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Wright, M. T. Menard, J. C. Wain, D. M. Donahue, H. C. Grillo, T. J. Lynch, N. C. Choi, and D. J. Mathisen Induction chemoradiation compared with induction radiation for lung cancer involving the superior sulcus Ann. Thorac. Surg., May 1, 2002; 73(5): 1541 - 1544. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. W. Rusch, D. J. Giroux, M. J. Kraut, J. Crowley, M. Hazuka, D. Johnson, M. Goldberg, F. Detterbeck, F. Shepherd, R. Burkes, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160) J. Thorac. Cardiovasc. Surg., March 1, 2001; 121(3): 472 - 483. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |